Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc eShunt™ System in the Treatment of Communicating Hydrocephalus

INTERVENTIONALInicio: 1 de oct de 2020ID: NCT04758611

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight

INTERVENTIONALInicio: 10 de feb de 2026ID: NCT07369011

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

INTERVENTIONALInicio: 21 de ago de 2018ID: NCT03486873

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

INTERVENTIONALInicio: 24 de may de 2024ID: NCT06345729

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

INTERVENTIONALInicio: 21 de jun de 2023ID: NCT05889182

ReclutandoFase 3ClinicalTrials.gov

Randomized, Multicenter, Multinational, Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Subjects With Stage IV NSCLC

INTERVENTIONALInicio: 15 de ago de 2023ID: NCT05668650

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

INTERVENTIONALInicio: 31 de dic de 2023ID: NCT06136624

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

INTERVENTIONALInicio: 12 de feb de 2025ID: NCT06834347

ReclutandoFase 3ClinicalTrials.gov

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

INTERVENTIONALInicio: 13 de dic de 2023ID: NCT06141473

ReclutandoFase 2ClinicalTrials.gov

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

INTERVENTIONALInicio: 11 de mar de 2025ID: NCT06833073

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

INTERVENTIONALInicio: 19 de nov de 2025ID: NCT07087054

ReclutandoFase 3ClinicalTrials.gov

A Randomised, Double-blind, Placebo-controlled Trial With an Open-label Extension to Assess the Pharmacokinetics, Safety, and Efficacy of Empagliflozin Tablets in Paediatric Patients With Chronic Kidney Disease (EMPA-KIDNEY® Kids)

INTERVENTIONALInicio: 9 de dic de 2025ID: NCT07107945

ReclutandoFase 3ClinicalTrials.gov

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19

INTERVENTIONALInicio: 6 de ago de 2021ID: NCT04910269

ReclutandoFase 3ClinicalTrials.gov

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

INTERVENTIONALInicio: 19 de jul de 2024ID: NCT06282575

ReclutandoClinicalTrials.gov

Effect of Consumption of a Dairy Product Designed for Pregnant and Lactating Women on the Composition of Human Milk. A Quasi-experimental Study in a Vulnerable Population

INTERVENTIONALInicio: 1 de ago de 2025ID: NCT07173881

ReclutandoClinicalTrials.gov

Institutional Registry of Haemorrhagic Hereditary Telangiectasia

OBSERVATIONALInicio: 1 de ene de 2010ID: NCT01761981

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

INTERVENTIONALInicio: 13 de mar de 2025ID: NCT06764485

ReclutandoClinicalTrials.gov

Real-world Evidence of First-line Treatment With Pediatric-like Protocol for Adolescents and Young Adults Patients Diagnosed With Philadelphia-negative Acute Lymphoblastic Leukemia

OBSERVATIONALInicio: 1 de mar de 2021ID: NCT05127148

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

INTERVENTIONALInicio: 6 de jun de 2024ID: NCT06056297

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

INTERVENTIONALInicio: 13 de ago de 2024ID: NCT06531824